PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8625964-2	1996	Notably, mast cells respond to C3a with the release of vasoactive substances, including histamine.	Histamine	88-97	complement C3	Homo sapiens	31-34	
7513741-1	1994	The complement peptides C3a and C5a have been shown previously to release histamine from human basophils but not human lung mast cells.	Histamine	74-83	complement C3	Homo sapiens	24-27	
7513741-3	1994	In concentration-response studies, both C3a and C5a released histamine in a concentration related manner with C5a being 40-50 times more potent.	Histamine	61-70	complement C3	Homo sapiens	40-43	
7513741-7	1994	In time-course studies, histamine release induced by C3a and C5a was complete within 15 seconds.	Histamine	24-33	complement C3	Homo sapiens	53-56	
7513741-10	1994	Both C3a and C5a at concentrations that induced 10-16% net histamine release caused a negligible release of the newly generated mediator, PGD2.	Histamine	59-68	complement C3	Homo sapiens	5-8	
7513741-12	1994	However, the activation site for C3a and C5a appears to be different to that for substance P as the substance P antagonist (D-Pro4, D-Trp7,9,10) SP4-11 inhibited histamine release stimulated by substance P but not that induced by C3a and C5a.	Histamine	162-171	complement C3	Homo sapiens	33-36	
1373170-1	1992	Incubation of either C3a, C3ades Arg, or synthetic analogues of the C-terminal sequence of C3a with purified rat peritoneal mast cells resulted in a rapid and dose-dependent histamine release.	Histamine	174-183	complement C3	Homo sapiens	21-24	
7679650-3	1993	When incubated with IL-3, these cells specifically liberated histamine on C3a stimulation.	Histamine	61-70	complement C3	Homo sapiens	74-77	
1282507-7	1992	Studies with the anaphylatoxin, C3a, and its analogues 21R and C3ades Arg on skin mast cells emphasized the importance of basic amino acids for histamine-liberating peptides.	Histamine	144-153	complement C3	Homo sapiens	32-35	
1373170-1	1992	Incubation of either C3a, C3ades Arg, or synthetic analogues of the C-terminal sequence of C3a with purified rat peritoneal mast cells resulted in a rapid and dose-dependent histamine release.	Histamine	174-183	complement C3	Homo sapiens	26-29	
6170591-3	1981	Chemically purified human C3a and C5a each caused histamine release from human basophils; C5a was more potent than C3a.	Histamine	50-59	complement C3	Homo sapiens	26-29	
1375610-6	1992	net histamine release, 20-30%) in a dose-related, temperature- and time-dependent fashion following stimulation with purified human C5a and C3a (over the ranges of 5 x 10(-8) M to 10(-7) M and 3 x 10(-7) M to 6 x 10(-6) M, respectively).	Histamine	4-13	complement C3	Homo sapiens	140-143	
1697689-5	1990	However, when basophils were pretreated with IL-3 at concentrations of only 0.01-1 unit/ml, they became responsive to C3a, releasing large amounts of histamine and also generating leukotrienes.	Histamine	150-159	complement C3	Homo sapiens	118-121	
1697689-8	1990	C3a-induced histamine release and leukotriene generation occurred rapidly in IL-3-primed cells, being complete after 0.5 and 2 min, respectively.	Histamine	12-21	complement C3	Homo sapiens	0-3	
3026724-1	1986	Anaphylatoxins, in particular C3a and C5a, have various biological activities which suggest a role as mediators of inflammatory reactions: they cause contraction of smooth muscle, histamine release, increase in capillary permeability, adhesion of leukocytes to vascular endothelium, leukocyte chemotaxis, and aggregation of platelets and leukocytes.	Histamine	180-189	complement C3	Homo sapiens	30-33	
3871207-6	1985	Histamine was found to partially mediate the vascular leakage induced by C3a and the initial (first 5 min) permeability response to the high concentration of C5a, whereas the subsequent leakage induced by the latter anaphylatoxin was unaffected by mepyramine pretreatment.	Histamine	0-9	complement C3	Homo sapiens	73-76	
2579381-3	1985	As a function of dose, C3a caused tachycardia, impairment of atrioventricular conduction, left ventricular contractile failure, coronary vasoconstriction, and histamine release.	Histamine	159-168	complement C3	Homo sapiens	23-26	
2579381-5	1985	The magnitude of C3a-induced tachycardia correlated with the amount of endogenous cardiac histamine released into the coronary effluent.	Histamine	90-99	complement C3	Homo sapiens	17-20	
2579381-7	1985	This suggests that histamine, leukotrienes, and vasoactive prostanoates may mediate the various cardiac effects of C3a.	Histamine	19-28	complement C3	Homo sapiens	115-118	
7047077-4	1981	Cleavage of C3 and C5 by either pathway yields the C3a and C5a anaphylatoxins which cause histamine release from mast cells and formation of the C5b6789 attack complex causes cell lysis.	Histamine	90-99	complement C3	Homo sapiens	51-54	
6170591-5	1981	The addition of C3a and C5a at suboptimal concentrations produced an additive effect of histamine release.	Histamine	88-97	complement C3	Homo sapiens	16-19	
89118-2	1979	On a molar basis, 5R was one-tenth and 8R was one-fifth as active as C3a in causing histamine release.	Histamine	84-93	complement C3	Homo sapiens	69-72	
7350527-1	1980	Investigation of the biological effects of the cleavage product, C3a, derived from the third component of complement has generally focused on the effects it exerts as an anaphylatoxin, that is, smooth muscle contraction and histamine release from mast cells and basophils.	Histamine	224-233	complement C3	Homo sapiens	65-68	
7011615-3	1980	Using immunofluorescence and pulse-label studies with 3H-labelled amino acids, histamine was shown to inhibit the secretion of newly synthesized C2, C4, C3, factor B and beta 1H globulin by monocytes in culture.	Histamine	79-88	complement C3	Homo sapiens	153-165	
7011615-5	1980	The observations that all monocytes in cultures containing histamine stained for C2, C4, and C3, factor B and beta 1H, when secretion was impaired, shows that all monocytes synthesize these proteins.	Histamine	59-68	complement C3	Homo sapiens	93-105	
7011615-7	1980	The anaphylotoxins, C3a and C5a, formed as a result of C3 and C5 cleavage, release histamine from mast cells and basophils.	Histamine	83-92	complement C3	Homo sapiens	20-23	
7011615-8	1980	Histamine, by inhibiting the production of C4, C2, and C3 and factor B by mononuclear phagocytes, inhibits further C3 and C5 cleavage by restricting the formation of C42, C423b and C3bBbP.	Histamine	0-9	complement C3	Homo sapiens	55-70	
30032131-9	2018	Our data suggests that down-regulation of C3aR expression by mediators present in allergic situations such as IL-4 or histamine has an anti-inflammatory impact by reducing the sensitivity to C3a-induced down-stream signaling, thereby contributing to the regulation of local inflammatory responses in the skin.	Histamine	118-127	complement C3	Homo sapiens	42-45	
109469-2	1979	Release of histaminase, one of two important histamine catabolizing enzymes, and beta-glucuronidase from polymorphonuclear leukocytes was solely dependent on particle-bound C3b (the larger cleavage product of the third component of complement) when fluid-phase complement was excluded.	Histamine	45-54	complement C3	Homo sapiens	173-176	
48505-2	1975	The peptides, derived from human or porcine complement proteins C3 and C5, were less potent than 48/80 but more potent than bradykinin in stimulating release of histamine from mast cells.	Histamine	161-170	complement C3	Homo sapiens	64-73	
803505-15	1975	Porcine C3a, like human C3a, was shown to contain a COOH-terminal arginyl residue essential for smooth muscle contraction and for induction of histamine release from mast cells.	Histamine	143-152	complement C3	Homo sapiens	8-11	
4097977-14	1970	These observations were consistent with the endogenous production of C3a and the resulting histamine release from mast cells.	Histamine	91-100	complement C3	Homo sapiens	69-72	
22155625-2	2012	C4a also inhibited histamine release from HMC-1 cells that were induced by recombinant C3a.	Histamine	19-28	complement C3	Homo sapiens	87-90	
24493825-8	2014	PBdMC released >10% histamine upon stimulation with anti-IgE, C3a, Substance P, and Compound 48/80, whereas CBdMC only reacted to C3a.	Histamine	23-32	complement C3	Homo sapiens	65-68	
26120516-7	2014	C5a and C3a cause the in vitro release of histamine and tryptase from HHMC.	Histamine	42-51	complement C3	Homo sapiens	8-11	
12612546-4	2003	C3a- and C5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basophils were also suppressed by exogenous immunoglobulins.	Histamine	55-64	complement C3	Homo sapiens	0-3	
18039528-8	2007	Finally, because C3a and C5a can stimulate the generation of nitric oxide along with the secretion of histamine and LTC4 from several cell types, the anaphylatoxins can bring about an increase in vascular permeability that facilitates eosinophil accumulation at sites of allergic inflammation.	Histamine	102-111	complement C3	Homo sapiens	17-20	
9585825-5	1998	It has been proved in vitro that aqueous extracts of some allergens produce the consumption of complement, by its usual via, in which the C1 component is involved, without the mediation of antibodies, generating anaphylotoxin C3a, which is a powerful releaser of histamine, as well as C3b, which participates in the regulation of the cellular immunitary system.	Histamine	263-272	complement C3	Homo sapiens	226-229